Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anup George"'
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0153286 (2016)
Anaemia is a major health burden worldwide. Although the finding of conjunctival pallor on clinical examination is associated with anaemia, inter-observer variability is high, and definitive diagnosis of anaemia requires a blood sample. We aimed to d
Externí odkaz:
https://doaj.org/article/b1da20dbdb6f494ba416260633a29fd1
Autor:
Thomas Martin, Joseph Mikhael, Roman Hajek, Kihyun Kim, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, Anup George, Tatiana Konstantinova, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau
Publikováno v:
Blood Advances. 6:4506-4515
The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6416388ee2b8971352d289622500df15
https://doi.org/10.1182/bloodadvances.2021006713
https://doi.org/10.1182/bloodadvances.2021006713
Autor:
Elizabeth M Moore, Hilary Blacklock, Cameron Wellard, Ruth Spearing, Luke Merriman, Sarah Poplar, Anup George, Bart Baker, Henry Chan, Zoe K McQuilten, Erica M Wood, Andrew Spencer
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(8)
Māori and Pacific peoples (MPP) in New Zealand (NZ) have poorer health outcomes than other ethnicities. However, this has not been clinically investigated in multiple myeloma (MM). Using data from the Australian and NZ Myeloma and Related Diseases R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dc7b87802c44a918bbeb8bfe23be629
https://pubmed.ncbi.nlm.nih.gov/35501256
https://pubmed.ncbi.nlm.nih.gov/35501256
Autor:
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Thomas Martin, Ivan Spicka, Kim Kihyun, Min Chang-Ki, Koh Youngil, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gabor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosinol, Munci Yagci, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan Crusoe, Tomas Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Tatiana Konstantinova, Javier De La Rubia, Kim Sung-Hyun, Angelo Maiolino, Anthony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, Alexander Luchinin, Irina Kryuchkova, Joaquin Martinez, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklos Egyed, Mario Petrini, Michele Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James Griffin, Hannah Hunter, Tonda Buck, Achilles Anagnostopoulos, Konstantinos Konstantopoulos, Tamas Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Ozdogu, Fahir Ozkalemkas
Publikováno v:
Lancet (London, England). 397(10292)
Summary Background Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide–dexamethasone and carfilzomib–dexamethasone for relapsed or refractory multiple myeloma. This phase 3, open-label study compared the effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3d1c48250ee8ce9e019676285572ba
https://pubmed.ncbi.nlm.nih.gov/34097855
https://pubmed.ncbi.nlm.nih.gov/34097855
Autor:
Mamta Garg, Helgi van de Velde, Gaëlle Asset, Hang Quach, Cyrille Hulin, Roman Hájek, Anup George, Sandrine Macé, Kihyun Kim, Tatiana Konstantinova, Marie-Laure Risse, Philippe Moreau, Kenshi Suzuki, Hanlon Sia, Joseph Mikhael, Thomas Martin
Publikováno v:
Blood. 136:7-8
Introduction: Achievement of minimal residual disease negative (MRD-) status in multiple myeloma (MM) is associated with improved progression-free survival (PFS) and overall survival (OS). Isatuximab (Isa) is an approved anti-CD38 IgG kappa monoclona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e3a418af1b03a5b3eb5cc55febd26b1
https://doi.org/10.1182/blood-2020-137681
https://doi.org/10.1182/blood-2020-137681
Autor:
Paula Marlton, Greg Hapgood, John F. Seymour, Ian Prosser, Janey M. Stone, Diana Zannino, Chi-Hung Hui, Anup George, Ian D. Lewis, Henry Miles Prince, Kenneth F. Bradstock
Publikováno v:
Leukemialymphoma. 60(4)
To improve complete remission (CR) rates by reducing toxicity and enhancing delivery, we created a modified hyper-CVAD/MA regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone/methotrexate, cytarabine) by reducing the cytarabine dose (3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::550ee7288d8382bbcaf2de33fc3ff09b
https://pubmed.ncbi.nlm.nih.gov/30547695
https://pubmed.ncbi.nlm.nih.gov/30547695